Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599092 · ClinicalTrials.gov registry record
Pituitary Tumor Surveillance: Pathogenic Correlation
A clinical trial of Pituitary Tumor, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- 1,250
- Enrollment target
- 1
- Study location
NCT00599092 is a study of Pituitary Tumor that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 1,250 participants, above the 174-participant average among 5 other Pituitary Tumor trials with a reported enrollment target (618% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00599092, a study of Pituitary Tumor, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- 1,250 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.
Conditions Studied
Study Locations (1)
California
- Cedars-Sinai Medical Center, Pituitary Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 1997-01 |
| Est. Completion | 2050-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00599092
The ClinicalTrials.gov registry entry for NCT00599092 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 5 other Pituitary Tumor trials with a reported enrollment target (618% higher). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pituitary Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT00599092 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00599092 about?
NCT00599092 is a clinical study titled "Pituitary Tumor Surveillance: Pathogenic Correlation". The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.
What is the current status of trial NCT00599092?
This trial is currently recruiting. The enrollment target is 1,250 participants. The study started on 1997-01. Estimated completion is 2050-12.
What conditions does trial NCT00599092 study?
This clinical trial studies the following conditions: Pituitary Tumor.
Who is sponsoring clinical trial NCT00599092?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00599092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pituitary Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Nasal Outcomes Using Saline Irrigations After Endonasal Pituitary Surgery
RECRUITING · NA
-
Long-Term Longitudinal QoL in Patients Undergoing EEA
RECRUITING
-
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.